Diabetes and Cancer

Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and diabetes treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis, 2) risk factors common to both diabetes and cancer, 3) possible biologic links between diabetes and cancer risk, and 4) whether diabetes treatments influence risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed.

[1]  A. Roddam,et al.  Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies , 2010, The Lancet. Oncology.

[2]  A. Nicolucci.  Epidemiological aspects of neoplasms in diabetes , 2010, Acta Diabetologica.

[3]  R. Bergenstal,et al.  Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. , 2010, The American journal of medicine.

[4]  M. Pollak,et al.  Insulin analogues and cancer risk: cause for concern or cause célèbre? , 2010, International journal of clinical practice.

[5]  H. Gerstein.  Does insulin therapy promote, reduce, or have a neutral effect on cancers? , 2010, JAMA.

[6]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[7]  A. Morisset,et al.  Prevention of gestational diabetes mellitus: a review of studies on weight management , 2010, Diabetes/metabolism research and reviews.

[8]  Laura Sciacca,et al.  Diabetes and cancer. , 2009, Endocrine-related cancer.

[9]  G. Landman,et al.  Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes , 2009, Diabetes Care.

[10]  P. Butler.  Insulin Glargine Controversy: A Tribute to the Editorial Team at Diabetologia , 2009, Diabetes.

[11]  Jürgen Rehm,et al.  Alcohol as a Risk Factor for Type 2 Diabetes , 2009, Diabetes Care.

[12]  K. Straif,et al.  A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. , 2009, The Lancet. Oncology.

[13]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[14]  D. Panagiotakos,et al.  Dietary patterns and prevention of type 2 diabetes: from research to clinical practice; a systematic review. , 2009, Current diabetes reviews.

[15]  F. Visseren,et al.  Obesity and Cancer: The Role of Dysfunctional Adipose Tissue , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[16]  K. Struhl,et al.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.

[17]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[18]  C. Currie,et al.  The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings , 2009, Diabetologia.

[19]  J. Stanford,et al.  Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study , 2009, Cancer Causes & Control.

[20]  J. McGill,et al.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study , 2009, Diabetologia.

[21]  H. Colhoun,et al.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.

[22]  U. Smith,et al.  Does diabetes therapy influence the risk of cancer? , 2009, Diabetologia.

[23]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Steineck,et al.  Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden , 2009, Diabetologia.

[25]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[26]  A. Renehan.  Bariatric surgery, weight reduction, and cancer prevention. , 2009, The Lancet. Oncology.

[27]  Bolin Liu,et al.  Metformin induces unique biological and molecular responses in triple negative breast cancer cells , 2009, Cell cycle.

[28]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[29]  L. Hemkens,et al.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study , 2009, Diabetologia.

[30]  L. Shaw,et al.  Expression and function of the insulin receptor substrate proteins in cancer , 2009, Cell Communication and Signaling.

[31]  V. Ehemann,et al.  Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. , 2009, Endocrine-related cancer.

[32]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[33]  J. Menéndez,et al.  Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells , 2009, Cell cycle.

[34]  Ross J. Harris,et al.  Circulating insulin‐like growth factor peptides and prostate cancer risk: A systematic review and meta‐analysis , 2009, International journal of cancer.

[35]  M. Pollak.  Do cancer cells care if their host is hungry? , 2009, Cell metabolism.

[36]  R. DeFronzo.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[37]  A. Thor,et al.  Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro , 2009, Cell cycle.

[38]  David M. Sabatini,et al.  Tumours with PI3K activation are resistant to dietary restriction , 2009, Nature.

[39]  M. Cazzaniga,et al.  Is it Time to Test Metformin in Breast Cancer Clinical Trials? , 2009, Cancer Epidemiology Biomarkers & Prevention.

[40]  M. Jensen,et al.  Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. , 2009, The American journal of medicine.

[41]  S. Sorrenti,et al.  The urokinase plasminogen activator system: a target for anti-cancer therapy. , 2009, Current cancer drug targets.

[42]  J. Meyerhardt,et al.  Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Menéndez,et al.  The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells , 2009, Cell cycle.

[44]  F. Ondrey,et al.  Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention , 2009, Clinical Cancer Research.

[45]  H. Werner,et al.  Insulin analogues display IGF‐I‐like mitogenic and anti‐apoptotic activities in cultured cancer cells , 2009, Diabetes/metabolism research and reviews.

[46]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[47]  A. Wolff,et al.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. , 2008, JAMA.

[48]  H. Masoudi,et al.  Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. , 2008, Cancer research.

[49]  S. Mayne,et al.  Dietary glycemic index, glycemic load, and risk of cancer: a prospective cohort study. , 2008, American journal of epidemiology.

[50]  D. Balzi,et al.  Sulphonylureas and cancer: a case–control study , 2008, Acta Diabetologica.

[51]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[52]  M. Stampfer,et al.  Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. , 2008, The Lancet. Oncology.

[53]  M. Pollak,et al.  Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. , 2008, Endocrine-related cancer.

[54]  J. Shikany,et al.  Dietary carbohydrate, glycemic index, and glycemic load in relation to colorectal cancer risk in the Women’s Health Initiative , 2008, Cancer Causes & Control.

[55]  N. Marchionni,et al.  Rosiglitazone and Risk of Cancer , 2008, Diabetes Care.

[56]  S. Jabbour.  Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? , 2008, International journal of clinical practice.

[57]  B. Zinman,et al.  The impact of diabetes on survival following breast cancer , 2008, Breast Cancer Research and Treatment.

[58]  H. Arnqvist,et al.  Mitogenic Effect of the Insulin Analogue Glargine in Malignant Cells in Comparison with Insulin and IGF-I , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[59]  P. Mitchell,et al.  Glycemic index, glycemic load, and chronic disease risk--a meta-analysis of observational studies. , 2008, The American journal of clinical nutrition.

[60]  P. Pisani.  Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies , 2008, Archives of physiology and biochemistry.

[61]  J. Cornuz,et al.  Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. , 2007, JAMA.

[62]  F. Hu,et al.  Glycemic index, glycemic load, and cereal fiber intake and risk of type 2 diabetes in US black women. , 2007, Archives of internal medicine.

[63]  N. Sonenberg,et al.  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. , 2007, Cancer research.

[64]  J. Manson,et al.  Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. , 2007, Cancer research.

[65]  D. Hum,et al.  Safety issues and prospects for future generations of PPAR modulators. , 2007, Biochimica et biophysica acta.

[66]  L. Maile,et al.  Role of the integrin αVβ3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress , 2007 .

[67]  B. Littenberg,et al.  Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System , 2007, BMC medicine.

[68]  M. Stampfer,et al.  Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts , 2007, British Journal of Cancer.

[69]  C. Mantzoros,et al.  Diabetes mellitus and risk of endometrial cancer: a meta-analysis , 2007, Diabetologia.

[70]  N. Qizilbash,et al.  Cancer risks in thiazolidinedione users compared to other anti‐diabetic agents , 2007, Pharmacoepidemiology and drug safety.

[71]  E. Giovannucci,et al.  The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. , 2007, Gastroenterology.

[72]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  G. Bray,et al.  Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes , 2007, Diabetes Care.

[74]  C. Roberts,et al.  Differential Activation of Insulin Receptor Substrates 1 and 2 by Insulin-Like Growth Factor-Activated Insulin Receptors , 2007, Molecular and Cellular Biology.

[75]  Anna Marie Mulligan,et al.  Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer , 2007, Breast Cancer Research and Treatment.

[76]  Graham A Colditz,et al.  Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. , 2006, Journal of the National Cancer Institute.

[77]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[78]  E. Giovannucci,et al.  A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[79]  A. Renehan,et al.  Obesity and cancer risk: the role of the insulin–IGF axis , 2006, Trends in Endocrinology & Metabolism.

[80]  Desmond E. Williams,et al.  The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth Study , 2006, Pediatrics.

[81]  M. Schulze,et al.  Body iron stores and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study , 2006, Diabetologia.

[82]  G. Colditz,et al.  Physical activity and survival after colorectal cancer diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  W. Willett,et al.  Adult weight change and risk of postmenopausal breast cancer. , 2006, JAMA.

[84]  C. Friedenreich,et al.  Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). , 2006, Journal of the National Cancer Institute.

[85]  D. Hunter,et al.  Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. , 2006, Endocrine-related cancer.

[86]  F Berrino,et al.  IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). , 2006, Endocrine-related cancer.

[87]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[88]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[89]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[90]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[91]  L. Wagenknecht,et al.  Smoking and incidence of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis Study. , 2005, Diabetes care.

[92]  S. Hankinson,et al.  Racial Differences in Premenopausal Endogenous Hormones , 2005, Cancer Epidemiology Biomarkers & Prevention.

[93]  C. Franceschi,et al.  Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice , 2005, Experimental Gerontology.

[94]  Sui Huang,et al.  PPARγ as a therapeutic target for tumor angiogenesis and metastasis , 2005 .

[95]  Graham A. Colditz,et al.  Physical activity and survival after breast cancer diagnosis , 2005 .

[96]  M. Woodward,et al.  Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.

[97]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[98]  S. Hankinson,et al.  A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[99]  M. Abdul-Ghani,et al.  High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. , 2005, The Israel Medical Association journal : IMAJ.

[100]  M. Thun,et al.  Diabetes and risk of prostate cancer in a prospective cohort of US men. , 2005, American journal of epidemiology.

[101]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[102]  M. Thun,et al.  Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.

[103]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[104]  J. Arnsten,et al.  Effect of Alcohol Consumption on Diabetes Mellitus , 2004, Annals of Internal Medicine.

[105]  I-Min Lee,et al.  Physical activity and cancer prevention--data from epidemiologic studies. , 2003, Medicine and science in sports and exercise.

[106]  B. Spiegelman,et al.  Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study , 2003, Breast Cancer Research and Treatment.

[107]  JoAnn E Manson,et al.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.

[108]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[109]  C. Friedenreich,et al.  Physical activity and cancer prevention: etiologic evidence and biological mechanisms. , 2002, The Journal of nutrition.

[110]  Kevin P. High,et al.  15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200224-JLR200 , 2002, Journal of Lipid Research.

[111]  M. Thun,et al.  American Cancer Society guidelines on nutrition and physical activity for cancer prevention , 2002, CA: a cancer journal for clinicians.

[112]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[113]  G. Atsumi,et al.  Magnitude of Peroxisome Proliferator-Activated Receptor-γ Activation is Associated With Important and Seemingly Opposite Biological Responses in Breast Cancer Cells , 2001, Journal of Investigative Medicine.

[114]  J. Halperin,et al.  Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. , 2001, Cancer research.

[115]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[116]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[117]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[118]  Russell E Glasgow,et al.  Smoking and diabetes. , 1999, Diabetes care.

[119]  A. Rosenbloom,et al.  Emerging epidemic of type 2 diabetes in youth. , 1999, Diabetes care.

[120]  M. Thun,et al.  Diabetes mellitus and pancreaticcancer mortality in a prospectivecohort of United States adults , 1998, Cancer Causes & Control.

[121]  C. Mantzoros,et al.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.

[122]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[123]  M. Mathieu,et al.  Insulin receptor expression and clinical outcome in node-negative breast cancer. , 1997, Proceedings of the Association of American Physicians.

[124]  M. Rechler,et al.  Insulin rapidly decreases insulin-like growth factor-binding protein-1 gene transcription in streptozotocin-diabetic rats. , 1992, Molecular endocrinology.

[125]  D. Powell,et al.  Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. , 1991, The Journal of biological chemistry.

[126]  D. Silverman,et al.  Cancer risk in patients with diabetes mellitus , 1991, Cancer Causes & Control.

[127]  R. Brand,et al.  Elevated insulin receptor content in human breast cancer. , 1990, The Journal of clinical investigation.

[128]  C. la Vecchia,et al.  Medical history and primary liver cancer. , 1990, Cancer research.

[129]  N. Legros,et al.  Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. , 1972, Cancer research.

[130]  E. Joslin,et al.  Diabetes and cancer. , 1959, The New England journal of medicine.

[131]  Robert H. Bell,et al.  Insulin receptor expression by human prostate cancers , 2009, The Prostate.

[132]  P. Goodwin,et al.  Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008 300(23):2754-64. PMID: 19088353 , 2009 .

[133]  D. Yee,et al.  Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. , 2007, Cancer research.

[134]  M. Thun,et al.  Erratum , 2007 .

[135]  L. Pollack,et al.  Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer , 2005, Nature Clinical Practice Oncology.

[136]  S. Hilsenbeck,et al.  Time-dependence of hazard ratios for prognostic factors in primary breast cancer , 2004, Breast Cancer Research and Treatment.

[137]  E. Rimm,et al.  Diabetes mellitus and risk of prostate cancer (United States) , 2004, Cancer Causes & Control.

[138]  E. Giovannucci.  American Institute for Cancer Research 11th Annual Research Conference on Diet, Nutrition and Cancer Insulin, Insulin-Like Growth Factors and Colon Cancer: A Review of the Evidence , 2001 .

[139]  R. Glasgow,et al.  Smoking and Diabetes , 2001 .

[140]  S. Haffner,et al.  Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans--a 7-year prospective study. , 1997, Obesity research.

[141]  C. la Vecchia,et al.  Selected medical conditions and risk of breast cancer. , 1997, British Journal of Cancer.